Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Skinosive currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These active matters are assigned to 2 distinct examiners and 2 distinct art units. The busiest examiner for the portfolio is ENGLISH, CONNOR KENNEDY, who is responsible for 1 pending office action. This indicates that the 2 pending office actions are split between 2 distinct examiners, with each examiner handling a portion of the workload. The presence of 2 distinct art units suggests that the company's innovations fall into different specialized categories within the biotechnology sector.
Practitioners should prepare for varied feedback as the 2 distinct examiners evaluate the pending applications independently. Because the 2 pending office actions are split between 2 distinct art units, the company must navigate different sets of examination guidelines. Studying the past behavior of ENGLISH, CONNOR KENNEDY is essential for the 1 pending office action under their review. A coordinated approach is necessary to ensure that arguments made to one of the 2 distinct examiners do not conflict with those made to the other. This distribution of 2 pending office actions across 2 distinct examiners requires a strategy that addresses the specific technical requirements of each unit while maintaining a cohesive overall patent strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637828 | BIOADHESIVE PARTICLES COMPRISING ACTIVE AGENTS, AND USES THEREOF | ARNOLD, ERNST V | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637828 | BIOADHESIVE PARTICLES COMPRISING ACTIVE AGENTS, AND USES THEREOF | ARNOLD, ERNST V | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17637828 | BIOADHESIVE PARTICLES COMPRISING ACTIVE AGENTS, AND USES THEREOF | ARNOLD, ERNST V | 1613 | §103§112 | Final Rejection | 11d overdue | Pending | Feb 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial